QRX-3

DRUG4 trials

Sponsors

Ebima Clifford Okundaye, Neukidney Inc.

Conditions

Acute Kidney InjuryAcute Renal Failure (ARF)Acute Tubular NecrosisChronic Kidney Disease (Stage 3-4)Chronic Kidney Disease (Stages 4 and 5)Chronic Kidney Disease Stages 3-5Chronic Kidney DiseasesDiabetic Kidney Disease

Phase 2

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Not yet recruitingNCT06866236

Ebima Clifford OkundayeAcute Kidney Injury, Chronic Kidney Diseases, Kidney Failure

Start: 2025-10-31End: 2027-07-31Target: 3000Updated: 2025-09-08

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

CompletedNCT06948292

Ebima Clifford OkundayeChronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease

Start: 2023-03-01End: 2024-10-30Updated: 2025-09-08

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Not yet recruitingNCT07161843

Ebima Clifford OkundayeAcute Renal Failure (ARF), Acute Tubular Necrosis

Start: 2026-06-30End: 2027-02-01Target: 500Updated: 2026-02-18

Unknown Phase

Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease

CompletedNCT07150338

Neukidney Inc.Chronic Kidney Disease (Stage 3-4), Chronic Kidney Disease (Stages 4 and 5), Proteinuria

Start: 2021-05-20End: 2022-11-20Updated: 2025-09-08